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Abstract
Background: Previous studies found that [18F]LSN3316612 was a promising positron emission tomography (PET)
radioligand for imaging O-GlcNAcase in nonhuman primates and human volunteers. This study sought to further
evaluate the suitability of [18F]LSN3316612 for human clinical research.
Methods: Kinetic evaluation of [18F]LSN3316612 was conducted in a combined set of baseline brain scans from 17
healthy human volunteers and test-retest imaging was conducted in 10 of these volunteers; another 6 volunteers
had whole-body scans to measure radiation exposure to body organs. Total distribution volume (VT) estimates were
compared for the one- and two-tissue compartment models with the arterial input function. Test-retest variability
and reliability were evaluated via mean difference and intraclass correlation coefficient (ICC). The time stability of VT
was assessed down to a 30-min scan time. An alternative quantification method for [18F]LSN3316612 binding
without blood was also investigated to assess the possibility of eliminating arterial sampling.
Results: Brain uptake was generally high and could be quantified as VT with excellent identifiability using the two-
tissue compartment model. [18F]LSN3316612 exhibited good absolute test-retest variability (12.5%), but the arithmetic
test-retest variability was far from 0 (11.3%), reflecting a near-uniform increase of VT on the retest scan in nine of 10
volunteers. VT values were stable after 110 min in all brain regions, suggesting that no radiometabolites accumulated in
the brain. Measurements obtained using only brain activity (i.e., area under the curve (AUC) from 150–180 min)
correlated strongly with regional VT values during test-retest conditions (R
2 = 0.84), exhibiting similar reliability to VT
(ICC = 0.68 vs. 0.64). Estimated radiation exposure for [18F]LSN3316612 PET was 20.5 ± 2.1 μSv/MBq, comparable to
other 18F-labeled radioligands for brain imaging.
Conclusions: [18F]LSN3316612 is an excellent PET radioligand for imaging O-GlcNAcase in the human brain. Alternative
quantification without blood is possible, at least for within-subject repeat studies. However, the unexplained increase of
VT under retest conditions requires further investigation.
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Introduction
O-GlcNAcylation is a common post-transcriptional gly-
cosylation that occurs extensively at the intracellular
level of the brain [1]. This reversible cycling is modulated
by two enzymes; O-linked β-N-acetylglucosamine (O-
GlcNAc) transferase attaches O-GlcNAc to a protein,
whereas O-GlcNAcase (OGA) removes it [2]. Since the dis-
covery of O-GlcNAcylation of tau and its impact on tau
phosphorylation, O-GlcNAcylation-related studies have rap-
idly increased in Alzheimer’s disease (AD) [3]. Notably, be-
cause hyperphosphorylated tau forms aggregates and
neurofibrillary tangles—one of the hallmarks of AD [4]—O-
GlcNAcylation and its relationship to phosphorylation have
become the subjects of considerable investigative interest
with regard to a group of neurodegenerative diseases collect-
ively called tauopathies. O-GlcNAcylation has been known
to stabilize microtubule-associated protein tau by hampering
hyperphosphorylation and aggregation [5]. Indeed, initial
ex vivo research supported the reciprocal relationship O-
GlcNAcylation and phosphorylation [6], and analysis of hu-
man brain tissue revealed lower levels of tau-specific and
overall O-GlcNAc in individuals with AD [7]. Furthermore, a
series of animal studies found that increased O-GlcNAcyla-
tion cycling by an OGA inhibitor reduced tau protein aggre-
gation and restored cognitive function [8–10]. Not
surprisingly, rising levels of brain O-GlcNAcylation has been
explored as a potential therapeutic strategy for attenuating
the progression of AD and other tauopathies; as a result,
potent and selective OGA inhibitors have been developed,
and early phase clinical trials with these agents have begun
[11, 12].
In this context, a positron emission tomography (PET)
radioligand capable of imaging OGA could improve our un-
derstanding of the pathophysiology of neurodegenerative dis-
eases, provide evidence of drug-target engagement, and help
with dose selection of therapeutic candidates. Previous stud-
ies from our laboratory reported initial PET results of
[18F]LSN3316612 (N-(5-(((2S,4S)-2-methyl-4-(6-fluoropyri-
din-2-yloxy) piperidin-1-yl)methyl)thiazol-2-yl)acetamide) in
both nonhuman primates and healthy human volunteers. In
nonhuman primates, [18F]LSN3316612 exhibited excellent
properties for quantifying OGA in the brain, including high
brain uptake with a high proportion of specific binding, lack
of radiometabolite interference with quantification, and feasi-
bility of quantification with compartmental modeling [13]. A
follow-up study reported similarly promising results in the
brains of eight healthy volunteers [14]; human brain uptake
was well quantified with compartmental modeling and
showed no evidence of accumulation of radiometabolites.
This study sought to further evaluate the suitability of
[18F]LSN3316612 for use in human clinical research.
Brain scans were evaluated from an additional set of vol-
unteers (for a combined sample of 17). In addition, test-
retest imaging was conducted in 10 volunteers, and 6
whole-body scans were conducted to measure radiation
exposure to organs of the body.
Material and methods
Radioligand synthesis
[18F]LSN3316612 was synthesized by a nucleophilic sub-
stitution reaction on a nitro-aryl precursor, as previously
described [13]. The nitro precursor (N-(5-(((2S,4S)-2-me-
thyl-4-(6-nitropyridin-2-yloxy)piperidin-1-yl)methyl)thia-
zol-2-yl)acetamide) was provided at Eli Lilly.
Participants
The entire population for both brain and whole-body
imaging consisted of 11 male and 12 female healthy vol-
unteers; 17 of these had brain scans and six had whole-
body scans (Table 1). All volunteers were free of current
medical or psychiatric illnesses as determined by medical
history, physical examination, electrocardiogram, urin-
alysis, and laboratory blood tests (complete blood count,
serum chemistries, and thyroid function test). The
volunteer’s vital signs were recorded before radioligand
injection and at 15, 30, 90, and 120 min post-injection.
Brain image acquisition and processing
Brain PET scans were acquired from 17 healthy volun-
teers with an mCT scanner (Siemens Medical Solution,
Cary, NC, USA). After a low-dose CT scan for attenu-
ation correction, [18F]LSN3316612 (188 ± 5 MBq) was
intravenously injected and PET data were acquired for
180 min with concurrent arterial blood sampling. Data
were reconstructed into 45 frames (6 × 0.5 min, 3 × 1
min, 2 × 2 min, 34 × 5 min) using a three-dimensional
ordered subset expectation-maximization algorithm.
Brain uptake was expressed as a standardized uptake
value (SUV), which normalizes for injected radioactivity
and body weight. For structural magnetic resonance
(MR) imaging, all participants underwent sagittal T1-
weighted brain MR, using a 3T Philips Achieva scanner
(Bothell, WA, USA) with turbo field echo sequence
(repetition time = 8.1 ms, echo time = 3.7 ms, flip angle
= 8, matrix = 181 × 256 × 256, voxel size = 1 × 0.983 ×
0.983 mm).
Image pre-processing—such as coregistration between
PET and MR, segmentation, and atlas normalization—
was performed with the PNEURO pipeline implemented
in PMOD 3.903 (Zurich, Switzerland). A total of 83 vol-
umes of interest were defined based on the Hammers’
probabilistic brain atlas [15] and the subject’s individual
MR image and subsequently combined into an individ-
ual template consisting of 16 regions that encompass the
entire lobes of the brain and the principal subcortical
structures: frontal, parietal, temporal, occipital, insula,
amygdala, hippocampus, cingulate, striatum, thalamus,
globus pallidus, brainstem, corpus callosum, cerebellar
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cortex, cerebellar white matter, and cerebral white mat-
ter. Regional time-activity curves were obtained by ap-
plying the template on the dynamic PET images
transformed into MR space. The quality of PET-MR cor-
egistration was visually assessed by a side-by-side com-
parison of PET, MR, and fused images at the end of
PNEURO pipeline.
For the test-retest study, 10 out of the 17 volunteers
who had a brain scan were scanned again on a different
day under identical procedures. The interval between
test and retest scans ranged from 8 to 150 days.
Measuring [18F]LSN3316612 in plasma
During the brain PET scan, arterial blood was continu-
ously monitored for 10 min at a rate of 5 mL/min, and
radioactivity was measured with a cross-calibrated coinci-
dence detector (PBS-101, Comecer, The Netherlands).
Manual arterial samples were also obtained at 3, 5, 10, 15,
30, 60, 90, 120, 150, and 180 min after [18F]LSN3316612
injection.
For all blood samples, plasma concentrations of
[18F]LSN3316612 were measured using an automatic
gamma counter and were corrected after separation
from radiometabolites using high-performance liquid
chromatography (HPLC), as previously described [16],
but with an X-Terra C18 column (10 μm, 7.8 × 300 mm;
Waters Corp., Milford, MA, USA) and a mobile phase of
MeOH:10 mM ammonium formate (75% by volume).
The extraction efficiency of the deproteinization method
(e.g., acetonitrile extraction) was quantified using the
radioactivity of the precipitate. The mean extraction effi-
ciency of the 10 blood samples obtained from each of
the 10 participants during a 180-min test scan was
79.6% ± 6.4% (N = 10) which showed no significant dif-
ference from the 82.5% ± 5.7% mean that was obtained
during the retest scans (P = 0.101). The plasma free frac-
tion (fP; the non-protein bound fraction) was measured
by ultrafiltration [16]. Using the blood-to-plasma ratios
determined from the manual samples, total plasma
radioactivity curves were obtained from measured whole
blood data from automatic sampling for the first 10 min,
then scaled to fit manual sample data. Total plasma
radioactivity and whole blood activity were then fitted to
a tri-exponential function. A Hill function [17] was used
to fit the unchanged parent fraction. A time-activity
curve of radiometabolite-corrected plasma parent radio-
activity was generated implicitly by the product of the
total plasma activity curve and parent fraction in PMOD,
which was used as the input function.
Tracer kinetic modeling
All kinetic analyses, including fitting blood curves, were
conducted with the PKIN module in PMOD. The out-
come measure, total distribution volume (VT), was
calculated using one-and two-tissue compartmental
models with noise equivalent count weighting and the
radiometabolite-corrected arterial input function fitted
to a tri-exponential function. Whole blood curves were
used to correct for activity in the vascular component,
assuming that blood volume was 5% of total brain vol-
ume. An optimal kinetic model was determined based
on the relative fitness of the model (i.e., Akaike informa-
tion criterion (AIC) and F test) and the identifiability of
VT (i.e., percent standard error (%SE) estimated from the
theoretical parameter covariance matrix).
Test-retest variability and reliability
Test-retest variability and absolute test-retest variability
between test and retest scans were calculated as follows:
Test retest variability %ð Þ
¼ Test value−Retest value
Test valueþ Retest valueð Þ=2 100
Absolute test retest variability %ð Þ
¼ j Test value−Retest value j
Test valueþ Retest valueð Þ=2 100
To assess test-retest reliability, the intra-class correl-
ation coefficient (ICC) of each region was calculated as
follows [18]:









Baseline brain Test Retest Whole body
Male:female (n) 8:9 5:5 5:5 3:3
Age (years) 40 ± 11 43 ± 11 43 ± 11 34 ± 16
Body weight (kg) 73 ± 17 72 ± 16 75 ± 17 69 ± 12
Injected activity (MBq) 187 ± 6 185 ± 7 189 ± 3 172 ± 47
Molar activity (MBq/nmol) 55 ± 22 45 ± 16 50 ± 13 64 ± 9
Injected mass dose (nmol/kg) 0.058 ± 0.033 0.069 ± 0.038 0.057 ± 0.016 0.040 ± 0.011
Data are presented as mean values (±SD)
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ICC ¼ BSMSS−WSMSS
BSMSSþWSMSS
where BSMSS and WSMSS are the mean sums of
squares between subjects and within subjects, respect-
ively. In the test-retest study, ICC value could range
from – 1 to 1, and values closer to 1 indicated better re-
liability [19].
Whole-body biodistribution and radiation dosimetry
To determine the radiation exposure to body organs, a
separate group of six healthy volunteers underwent a
whole-body PET scan after intravenous administration
of [18F]LSN3316612 (172 ± 47 MBq). Dynamic scans
were acquired using the same mCT scanner in seven
contiguous segments from top of the head to mid-thigh
in 14 frames of increasing duration (75 s to 15 min) for
a total scan time of 120 min.
Thirteen source organs that could be identified as hot
uptake foci on PET images were generously delineated
on the tomographic images to ensure that all accumu-
lated radioactivity in each organ was encompassed using
PMOD: brain, heart, lungs, spleen, liver, kidneys, gall-
bladder, red marrow, stomach, testes/ovaries, urinary
bladder, and small intestine. Uptake in the source organs
was corrected with a recovery coefficient based on the
average activity of the frames of the whole-body dynamic
scan using large regions of interest drawn semi-
automatically around the body. The average recovery co-
efficient of the 6 volunteers was 90%. The radioactivity
concentration, measured without decay correction, was
expressed as a percentage of injected dose for each
organ. The organ residence time was calculated as the
area under the time-activity curve using the trapezoid
rule and physical decay after the last frame. Because the
total red marrow present in the lumbar vertebrae
accounts for ~ 12.3% of the mass of red marrow in the
whole body [20], the red marrow final residence time
was obtained by dividing the residence time in the lum-
bar vertebrae by 0.123. Values for the gastrointestinal
tract were generated by the International Commission
for Radiation Protection (ICRP) model in OLINDA/
EXM1.1 [21] as activity entering the small intestine [22].
To obtain the residence time for the remainder of the
body, residence times for all source organs were
summed and then subtracted from the theoretical value
of 2.65 h (=18F half-life/ln2).
Statistical analysis
Quantitative results are presented as mean ± standard
deviation (SD) unless otherwise noted. Differences be-
tween the test and retest groups were analyzed using a
two-way t test, and those among the three groups of vol-
unteers using the one-way analysis of variance
(ANOVA). Bonferroni correction was used for multiple
comparisons of each between-group comparison. The
correlation between continuous variables was evaluated
with linear regression analysis. Statistical significance
was set at P < 0.05, and all statistical analyses were con-
ducted using GraphPad Prism 5 (GraphPad Software, La
Jolla, CA, USA).
Results
Study population and injection parameters
As noted above, 17 baseline scans were analyzed for kin-
etic evaluation of [18F]LSN3316612 in the brain; 7 volun-
teers had a single scan and 10 volunteers had test-retest
scans. An arbitrary decision was made to use the first scan
for those volunteers who had test-retest scans. Results for
8 of the 17 volunteers have previously been reported [14],
and 1 of those volunteers went on to have a retest scan. A
separate set of 6 volunteers underwent whole-body scans
to evaluate biodistribution and radiation dosimetry. No
significant differences were observed between the three
groups of volunteers or between the test and retest studies
with regard to injected activity, molar activity, and injected
mass dose (Table 1).
[18F]LSN3316612 uptake in brain
After intravenous injection of [18F]LSN3316612, radio-
activity in the brain increased rapidly, reached its max-
imum at 20–30 min with a mean peak SUV of ~ 5, and
washed out slowly thereafter (Fig. 1). [18F]LSN3316612
showed widespread and moderately high uptake in the
brain preferentially along grey matter regions (Fig. 2). The
highest radioactivity concentrations (SUV) were observed
in the frontal cortex (~ 5.1), followed by the striatum and
occipital cortex (~ 5.0). The lowest radioactivity concen-
trations were observed in the corpus callosum (~ 2.3),
brainstem (~ 3.3), and cerebral white matter (~ 3.5). There
was almost no uptake of radioactivity in the skull, suggest-
ing that little, if any, radiodefluorination occurred.
Metabolism and clearance of radioligand in plasma
After an initial peak at about 1.5 min, the concentration
of parent radioligand in plasma decreased rapidly and
was well fitted to a triexponential curve (Fig. 3a). The
concentration of parent radioligand was equal to that of
all radiometabolites at about 15 min (Fig. 3b). The
HPLC radiochromatogram of plasma at 120 min identi-
fied at least five radiometabolites, all of which were less
lipophilic than the parent radioligand (Fig. 3c). The fP of
parent radioligand was 4.2 ± 1.1%.
Tracer kinetic evaluation of [18F]LSN3316612 in brain
Using serial measurements of radioactivity in the brain
and the concentration of parent radioligand in arterial
plasma, regional OGA density was well quantified as VT
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Fig. 1 T1-weighted magnetic resonance (MR) and [18F]LSN3316612 positron emission tomography (PET) images of a healthy volunteer. Although
the brain had high uptake of radioactivity, the skull had virtually none. The concentration of radioactivity in the brain is expressed as standardized
uptake values (SUV), which was measured from 120 to 180 min
Fig. 2 Time-activity curves for three brain regions after injection of [18F]LSN3316612. Points and bars represent mean standardized uptake values
(SUV) and standard deviations (SD), respectively, which were measured from 17 healthy volunteers
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using a two-tissue compartment model. Compared to
the one-tissue compartment model, the two-tissue com-
partment fit the data better both on visual inspection
(Fig. 4) and statistical comparison. That is, the AIC was
lower in the two-tissue compartment model than in the
one-tissue compartment model (545.5 and 640.7, re-
spectively; P = 0.004), and F tests indicated a signifi-
cantly better fit for the two-tissue compartment model.
These results are consistent with the radioligand having
two kinetically distinct binding sites: a nonspecific bind-
ing site with low affinity and rapid equilibration, and a
specific binding site with high affinity and slow
equilibration.
Using the two-tissue compartment model, the mean
regional VT (mL·cm
−3) was 12.2 and ranged from 7.9 to
17.6 (Table 2). The identifiability of VT was excellent,
with standard error (SE) less than 10% for all brain re-
gions. The three brain regions with the highest VT were
the amygdala (17.6), hippocampus (15.5), and cingulate
region (14.5), and the three regions with the lowest VT
were brainstem (7.9), corpus callosum (8.0), and white
matter (9.1) (Table 2). The estimated rate constants of
the whole brain were 0.301 ± 0.155 mL·min−1·mL−1 for
K1, 0.113 ± 0.076 min
−1 for k2, 0.092 ± 0.061 min
−1 for
k3, and 0.026 ± 0.007 min
−1 for k4, respectively. The
identifiability of the rate constants was excellent; the
mean SE was less than 10% (range 1.8–8.6%) for K1, k2,
and k4, and it was 11.6% for k3. The VT of the whole
brain did not significantly differ between men and
women and did not correlate with age. However, the
sample size was small (n = 17), and the age range was
limited (23–57 years old).
Fig. 3 Parent radioligand and radiometabolite profile in plasma after injection of [18F]LSN3316612. a The mean concentration (±SD) of [18F]LSN3316612 in
plasma from 17 healthy volunteers. b The fractions (±SD) of parent radioligand and radiometabolites in plasma from 17 healthy volunteers. c High-performance
liquid chromatography (HPLC) radiochromatogram of plasma content at 120 min after injection of [18F]LSN3316612 in one healthy volunteer
Fig. 4 Pharmacokinetic fitting of brain time-activity curves using one- and two-tissue compartment models. The two-tissue (2TCM, black lines)
compartment model better fit the measured standardized uptake values (SUV) than the one-tissue (1TCM, red dotted line) compartment model,
both visually and statistically
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Test-retest variability and reliability
Variability of VT for the test-retest scans was good. How-
ever, reliability was only modest, in part because the retest
VT of the whole brain was higher than that of the test scan
in 9 out of 10 volunteers (Additional file 1: Table S1), with
the mean value increased by 12.1% (P = 0.012). Test-retest
variability and absolute test-retest variability were 11.3%
and 12.5%, respectively, across all brain regions. The mean
ICC was 0.64. In addition, ICC was relatively poor for the
amygdala (0.42) and hippocampus (0.41), which were the
regions with highest VT.
With regard to test-retest scans, the interval between
the two scans was 49 ± 47 days (range 8–150 days). Inves-
tigation of the interval between test and retest, seasonal or
diurnal variations, molar activity, injected mass dose of
the test scan, and fP found that none of these factors cor-
related with the increase in VT (Additional file 2: Table
S2). Although plasma glucose was 13.6% lower on retest
compared to test scans, the significance (P = 0.018) did
not survive multiple comparison tests.
Time stability of VT
The time stability of VT was evaluated by fitting the PET
data with truncated acquisition times ranging from 0–30
to 0–180 min; these were expressed as a percentage of
the value determined with the entire 180-min scan.
Regional VT value asymptotically reached the terminal
value of VT (Fig. 5). For all brain regions, the average VT
values converged within 10% of their terminal values by
110 min. The hippocampus was the slowest region to
reach the stable VT value with 91% of the terminal value
at 110 min, while the cerebellum was the fastest, with
92% in only 60 min. The relatively stable VT values for
the last 70–120 min are consistent with the lack of accu-
mulation of radiometabolites in the brain. That is, up-
take and washout of brain radioactivity could be
explained by the input of only parent radioligand.
Alternative quantification of [18F]LSN3316612 binding
Because it uses both brain and plasma concentrations of
radioactivity, VT is the ‘gold standard’ against which sim-
plified approaches are compared. For this study, three po-
tential ways of avoiding arterial blood sampling, thus
simplifying the experimental methods, were considered.
The first and arguably best approach would have been to
use a reference region that contained no receptors. How-
ever, blocking studies in monkeys showed that all brain re-
gions, including white matter, had displaceable uptake
[13]. Second, we considered whether brain uptake by itself
might be able to substitute for measures like VT. We
found that among three 30-min time intervals (150–180
min, 120–150 min, and 90–120 min), the AUC of 150–
180 min (AUC150–180) correlated best with regional VT
calculated using arterial input function (R2 0.84, 0.81, and
0.74, respectively). However, although AUC150–180 corre-
lated strongly with VT on test and retest scans in an indi-
vidual volunteer, it correlated poorly with VT when tested
across all 17 volunteers (Fig. 6a). Third, we considered
whether a few blood samples could substitute for the en-
tire input function by normalizing brain activity to the
concentration of parent radioligand in arterial plasma—
i.e., AUC/CP150–180. This normalization slightly improved
the correlation with VT across all 17 volunteers (Fig. 6b),
but the reliability in test-retest scans of AUC/CP150–180
(ICC = 0.18) was much worse than that of AUC150–180 by
itself (ICC = 0.68; Table 3). In summary, none of these
three simplifications were useful in comparing OGA dens-
ities between individuals. However, brain activity by itself
(AUC150–180) might be used for repeated studies in a sin-
gle volunteer (e.g., to measure enzyme occupancy by a
therapeutic candidate) but would need to be corrected for
the consistent trend of the retest scan being higher than
the test scan.
Whole-body biodistribution and radiation dosimetry
Whole-body images were notable for early distribution
in the blood pool, accumulation in the target organ (i.e.,
brain), and excretion via urinary tract (Fig. 7). The brain
had high radioactivity concentration, with a peak of
about 6% of the injective dose at 30 to 40 min post-














Globus pallidus 11.5 25.0
Cerebellum 11.3 22.3
Thalamus 11.2 22.8
White matter (WM) 10.3 26.2
Cerebellar WM 9.1 23.7
Corpus callosum 8.0 36.8
Brainstem 7.9 24.5
Mean 12.2 24.9
COV coefficient of variation
aVT was calculated using a two-tissue compartment model. Values represent
the mean and coefficient of variation (COV = mean/SD) from the baseline
scans of 17 healthy volunteers
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injection. The liver and brain had the longest resi-
dence times (0.166 ± 0.008 and 0.160 ± 0.011 h, re-
spectively). The three organs with the highest
exposure (μSv/MBq) were the urinary bladder (86.4),
brain (32.2), and liver (30.4) (Additional file 3: Table
S3). The mean effective dose derived from six healthy
volunteers was 20.5 ± 2.1 μSv/MBq. Thus, injection
of 185 MBq of [18F]LSN3316612 would lead to an ef-
fective dose of 3.8 mSv; this dose is similar to that of
other 18F-labeled radioligands used for brain imaging
[23].
Discussion
The present study found that [18F]LSN3316612 was an
excellent PET radioligand for quantifying OGA in the
human brain with the exception of an unexplained in-
crease in VT on retest scanning in nine of 10 volunteers.
Brain uptake was generally high and could be quantified
as VT with excellent identifiability using a two-tissue
compartment model. [18F]LSN3316612 exhibited good
absolute test-retest variability (~ 12.5%), but the arith-
metic test-retest variability was far from 0 (~ 11.3%),
reflecting an almost uniform increase of VT on retest
Fig. 5 Time stability analysis of the total distribution volume (VT) of radioactivity within three brain regions. VT was calculated via a two-tissue
compartment model and normalized to the terminal VT value at 180 min. Points represent the mean normalized VT (±SD) from 17 healthy volunteers
Fig. 6 Correlation of the “gold-standard” measurement of whole-brain total distribution volume (VT) and two more simplified values. a Area
under the brain time-activity curves measured from 150 to 180 min (AUC150–180). b The same value normalized (i.e., divided) by the mean
concentration of parent radioligand in arterial plasma measured at 150 and 180 min (AUC/CP150–180). The points represent individual values from
17 healthy volunteers. The line represents a linear fit of the points
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scanning. VT values were stable after 110 min of scan-
ning in all regions, suggesting that radiometabolites did
not accumulate in the brain. Efforts to investigate an al-
ternative quantification method for [18F]LSN3316612
binding without blood to assess the possibility of elimin-
ating arterial sampling found that measurements ob-
tained using only brain activity (i.e., AUC from 150 to 180
min) were strongly correlated with regional VT values
within an individual volunteer during test and retest con-
ditions (R2 = 0.84), and similar reliability to VT was ob-
served (ICC = 0.68 for AUC150–180 and 0.64 for VT).
Despite the promising characteristics of [18F]LSN3316612,
the unexplained increase of VT under retest conditions re-
quires further investigation before the radioligand can be
widely used. In this study, the “gold standard” measurement
of OGA density (i.e., VT) in retest scans was greater than that
in the test scans in 9 out of 10 volunteers, with an average in-
crease of 12.1%. This unexpected increase may reflect two
possibilities. The first is that OGA levels actually increased
on retest scans, and the second is that our measurement of
VT was flawed. With regard to the first possibility, several
factors were examined that might correlate with and thereby
Table 3 Variability and reliability of test-retest parameters from 10 healthy volunteers after injection of [18F]LSN3316612
Parametera Source Testb Retestb TRV (%) aTRV (%) ICC
VT Brain and plasma 13.7 (19.2) 15.3 (19.6) 11.3 12.5 0.64
AUC150–180 Brain 102.2 (16.3) 103.6 (11.9) 1.8 9.0 0.68
AUC/CP150–180 Brain and plasma 654.1 (46.2) 661.1 (19.7) 6.5 31.9 0.18
Plasma parent
AUC0–∞
Plasma 105.9 (20.3) 96.0 (20.3) − 9.7 12.3 0.69
Brain
AUC0–∞
Brain 1428.2 (23.3) 1445.5 (20.6) 1.6 13.3 0.78
TRV test-retest variability, aTRV absolute test-retest variability, ICC intraclass correlation coefficient, VT total distribution volume, AUC area under the curve, TAC
time-activity curve
aThe measured parameters were VT total distribution volume (mL·cm
−3); AUC150–180 area under the curve of brain TAC of 150–180 min; AUC/CP150–180 normalized
AUC150–180 to mean parent radioactivity concentration in arterial plasma; AUC0–∞ area under the curve estimated from 0 min to infinity
bData are presented as mean with coefficient of variation (%) in parentheses
Fig. 7 Whole-body images of a healthy male at 4, 30, and 120 min after [18F]LSN3316612 injection. The images are displayed in standardized
uptake value (SUV) as a two-dimensional compression with maximal intensity projected (MIP) forward to emphasize contrast at the edge of
organs. The images are decay-corrected to time of injection
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explain an increase in retest scan. These included interval be-
tween test and retest, seasonal or diurnal variations, molar
activity, injected mass dose of the test scan, fP, image acquisi-
tion and processing, and the volunteers’ laboratory test re-
sults (Additional file 2: Table S2). During the entire course of
the study, factors such as variation of dose calibrator, well
counter, and HPLC were all closely monitored, and we found
no significant change in the external detectors related to
radioactivity measurement. Therefore, none of these factors,
we believe, contributed to the increase of VT. Nevertheless,
the sample size was small (n = 10) and may have had inad-
equate power to detect true effects.
The second, and more likely, the possibility is that our
measurement of VT was flawed in some way. Indeed, the
data suggested potential errors in measuring the input
function, i.e., the concentration of parent radioligand in
plasma over time. In particular, the variability and reli-
ability of only brain activity (i.e., AUC150–180) was as
good as or slightly better than that of VT, which uses
brain and plasma data. Addition of mean parent concen-
tration in plasma during the last 30 min (i.e., AUC/
CP150–180) worsened the variability and reliability in
comparison to only AUC150–180. To explore whether
measurement of the input function was flawed, we mea-
sured the AUC from time zero to infinity (AUC0–∞) of
the parent radioligand in plasma to determine how it
may have affected VT. Please note that VT = AUC0–∞ of
brain curve/AUC0–∞ of the plasma curve. We found that
the AUC0–∞ of the plasma curve was 8.6% lower on re-
test compared to test scans, which would explain most
of the increase in VT (12.1%). To determine which com-
ponent of the plasma curve might have been measured
inaccurately, we explored tri-exponential fitting of the
plasma curve, which identified three half-lives (1.0 ± 0.4,
8.0 ± 3.3, and 140.7 ± 39.2 min, respectively). The third
(slowest) component contributed most (76.3%) of the
AUC0–∞. Thus, sampling for only 180 min might inad-
equately define an exponent with a half-life of 141 min.
In addition, the concentration of radioactivity in plasma
was decreasing and difficult to measure. As a result, we
suspect, but are not certain, that errors may have oc-
curred in the measurement of the plasma input function
to increase VT on retest scans. However, we cannot ex-
plain why a consistent bias would have existed so that
plasma AUC0–∞would be lower on retest. A study with a
larger sample size and longer plasma sampling might
help answer these questions.
The average VT values in the 17 volunteers who had brain
scans reached 90% of terminal 3-h values at 110 min and
remained stable thereafter. This indicates that no trouble-
some radiometabolites entered the brain. Regions with high
VT (e.g., hippocampus) were slower to reach stable VT than
regions with lower VT (e.g., cerebellum), consistent with the
notion that higher enzyme density regions require a longer
time to reach equilibrium. The evaluation of time stability re-
vealed that the [18F]LSN3316612 PET scan time could be re-
liably shortened to 120 min; however, time stability would
need to be re-evaluated within disease-specific groups be-
cause the equilibrium time might change depending on the
degree of reduced OGA expression and decreased blood flow
that can occur in tauopathies.
Following the injection of [18F]LSN3316612, the whole-
body distribution of radioactivity reflected both the distri-
bution of OGA and the metabolism of the radioligand.
OGA is expressed in relatively high density in the brain,
gastrointestinal tract, exocrine glands, and immune system
[24, 25]. Accordingly, whole-body [18F]LSN3316612 PET
exhibited high accumulation in the brain, small bowel, sal-
ivary glands, and spleen. Similarly, uptake in the lumbar
vertebrae, which contain approximately 12.3% of all red
marrow in the body [20], likely reflected uptake in
hematopoietic stem cells in the red marrow [25]. Most of
the radioactivity was in the bone marrow and not in distal
appendicular bones without red marrow, suggesting that
negligible defluorination, if any, occurred. In addition to
reflecting the distribution of OGA in the body, radioactiv-
ity also likely reflected metabolism due to the hepatobili-
ary tract excretion of radiometabolites via urine—e.g., a
glucuronidated radiometabolite of the lipophilic radioli-
gand. The urinary bladder also received relatively high ex-
posure, although this was probably due to long retention
of urine during the 3-h PET scan and could therefore be
modestly lowered during a typical 2-h scan and by imme-
diate voiding after completion of PET scan. The effective
dose (μSv/MBq) of [18F]LSN3316612 (20.5 ± 2.1) was
similar to that of other 18F-radioligands used for brain im-
aging (20.8 ± 6.7 for 21 radioligands) [23].
Conclusions
Taken together, our results suggest that [18F]LSN3316612
is an excellent radioligand for use in clinical research. This
ligand shows promise for elucidating the pathophysiology
of neurogenerative diseases and facilitating drug develop-
ment by providing in vivo measures of target engagement
and enzyme occupancy. However, further studies are
needed to fully understand the unexplained increase in VT
under retest conditions before the radioligand can be
widely used.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13550-020-0616-4.
Additional file 1: Table S1. Brain region test-retest variability and reli-
ability for total distribution volume (VT) measurements in 10 healthy vol-
unteers injected with [18F]LSN3316612.
Additional file 2: Table S2. Demographic and imaging variables for
the 10 healthy volunteers in the test-retest study.
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Additional file 3: Table S3. Radiation dose estimates from six healthy
volunteers injected with [18F]LSN3316612.
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